Soligenix (NASDAQ:SNGX), Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and address unmet medical needs in biodefense. Founded in 2000 and headquartered in Princeton, New Jersey, Soligenix leverages proprietary technologies to create novel therapeutic and vaccine candidates. The company’s core mission is to advance innovative solutions for conditions lacking effective treatments, particularly in the areas of supportive oncology care, inflammatory diseases and next‐generation vaccines.
Soligenix’s pipeline includes late‐stage programs such as dusquetide (SGX942), an investigational therapy designed to reduce the severity and duration of oral mucositis in head and neck cancer patients undergoing chemoradiation. The company is also developing SGX301, a topical formulation of synthetic hypericin for the treatment of cutaneous T‐cell lymphoma, and other immunomodulatory compounds targeting gastrointestinal graft‐versus‐host disease. In the biodefense space, Soligenix applies its ThermoVax® technology platform to produce heat‐stable vaccines against potential biothreat agents, including Ricin Toxin Vaccine (RiVax®) and an enhanced Anthrax Vaccine Candidate (AV7909).
Soligenix operates on both domestic and international fronts, collaborating with U.S. government agencies such as the Biomedical Advanced Research and Development Authority (BARDA) as well as academic and nonprofit research centers. These partnerships support development, manufacturing and regulatory activities aimed at ensuring rapid response capabilities to public health emergencies. Through strategic alliances, the company seeks to expand access to its vaccine candidates and therapeutic programs across North America, Europe and emerging markets.
The company is led by a seasoned management team with extensive experience in biopharma development, regulatory affairs and strategic partnerships. Christopher J. Schaber, Ph.D., serves as Chairman and Chief Executive Officer, bringing over 25 years of leadership in specialty pharmaceutical and biotechnology ventures. Supported by a board of directors with deep expertise in clinical development and global commercialization, Soligenix continues to advance its portfolio with the goal of delivering safe, effective treatments for patients with limited therapeutic options.
